{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T13:58:21Z","timestamp":1790863101580,"version":"4.1.0"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND:<\/jats:title>\n                    <jats:p>Currently no ideal alternative exists for heparin for cardiopulmonary bypass (CPB). Dabigatran is a direct thrombin inhibitor for which a reversal agent exists. The primary end point of the study was to explore whether Dabigatran was an effective anticoagulant for 120 minutes of simulated CPB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>The study was designed in 2 sequential steps. Throughout, human blood from healthy donors was used for each experimental step. Initially, increasing concentrations of Dabigatran were added to aliquots of fresh whole blood, and the anticoagulant effect measured using kaolin\/tissue factor\u2013activated thromboelastography (rapidTEG). The dynamics of all thromboelastography (TEG) measurements were studied with repeated measures analysis of variance (ANOVA). Based on these data, aliquots of blood were treated with high-concentration Dabigatran and placed in a Chandler loop as a simple ex vivo bypass model to assess whether Dabigatran had sufficient anticoagulant effects to maintain blood fluidity for 2 hours of continuous contact with the artificial surface of the PVC tubing. Idarucizumab, humanized monoclonal antibody fragment, was used to verify the reversibility of Dabigatran effects. Finally, 3 doses of Dabigatran were tested in a simulated CPB setup using a heart\u2013lung machine and a commercially available bypass circuit with an arteriovenous (A-V) loop. The primary outcome was the successful completion of 120 minutes of simulated CPB with dabigatran anticoagulation, defined as lack of visible thrombus. Thromboelastographic reaction (R) time was measured repeatedly in each bypass simulation, and the circuits were continuously observed for clot. Scanning Electron Microscopy (SEM) was used to visualize fibrin formation in the filters meshes during CPB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>In in vitro blood samples, Dabigatran prolonged R time and reduced the dynamics of clot propagation (as measured by speed of clot formation [Angle], maximum rate of thrombus generation [MRTG], and time to maximum rate of thrombus generation [TMRTG]) in a dose-dependent manner. In the Chandler Loop, high doses of Dabigatran prevented clot formation for 120 minutes, but only at doses higher than expected. Idarucizumab decreased R time and reversed anticoagulation in both in vitro and Chandler Loops settings. In the A-V loop bypass simulation, Dabigatran prevented gross thrombus generation for 120 minutes of simulated CPB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>Using sequential experimental approaches, we showed that direct thrombin inhibitor Dabigatran in high doses maintained anticoagulation of blood for simulated CPB. Idarucizumab reduced time for clot formation reversing the anticoagulation action of Dabigatran.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1213\/ane.0000000000005089","type":"journal-article","created":{"date-parts":[[2020,8,23]],"date-time":"2020-08-23T13:02:05Z","timestamp":1598187725000},"page":"566-574","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":12,"title":["High-Dose Dabigatran Is an Effective Anticoagulant for Simulated Cardiopulmonary Bypass Using Human Blood"],"prefix":"10.1213","volume":"132","author":[{"given":"Sergiy M.","family":"Nadtochiy","sequence":"first","affiliation":[{"name":"From the Department of Anesthesiology and Perioperative Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aksana","family":"Baldzizhar","sequence":"additional","affiliation":[{"name":"From the Department of Anesthesiology and Perioperative Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsiana","family":"Stefanos","sequence":"additional","affiliation":[{"name":"From the Department of Anesthesiology and Perioperative Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyong","family":"Feng","sequence":"additional","affiliation":[{"name":"From the Department of Anesthesiology and Perioperative Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kade E.","family":"O\u2019Leary","sequence":"additional","affiliation":[{"name":"From the Department of Anesthesiology and Perioperative Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen L.","family":"Jones-Smith","sequence":"additional","affiliation":[{"name":"From the Department of Anesthesiology and Perioperative Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald E.","family":"Angona","sequence":"additional","affiliation":[{"name":"From the Department of Anesthesiology and Perioperative Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Eaton","sequence":"additional","affiliation":[{"name":"From the Department of Anesthesiology and Perioperative Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,8,20]]},"reference":[{"key":"R1-20250502","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1051\/ject\/201850005","article-title":"STS\/SCA\/AmSECT Clinical practice guidelines: anticoagulation during cardiopulmonary bypass.","volume":"50","author":"Shore-Lesserson","year":"2018","journal-title":"J Extra Corpor Technol"},{"key":"R2-20250502","first-page":"367284","article-title":"Tissue factor, blood coagulation, and beyond: an overview.","volume":"2011","author":"Chu","year":"2011","journal-title":"Int J Inflam"},{"key":"R3-20250502","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.jacc.2019.08.1028","article-title":"Anticoagulation with an inhibitor of factors XIa and XIIa during cardiopulmonary bypass.","volume":"74","author":"Pireaux","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R4-20250502","doi-asserted-by":"crossref","first-page":"CR105","DOI":"10.12659\/MSM.882465","article-title":"The influence of heparin resistance on postoperative complications in patients undergoing coronary surgery.","volume":"18","author":"Knapik","year":"2012","journal-title":"Med Sci Monit"},{"key":"R5-20250502","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/00003643-200105000-00007","article-title":"Risk factors for fatal myocardial infarction after coronary bypass graft surgery.","volume":"18","author":"Ranucci","year":"2001","journal-title":"Eur J Anaesthesiol"},{"key":"R6-20250502","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1124\/jpet.119.257725","article-title":"Protamine sulfate induces mitochondrial hyperpolarization and a subsequent increase in reactive oxygen species production.","volume":"370","author":"Ramzan","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"key":"R7-20250502","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199105303242206","article-title":"Heparin.","volume":"324","author":"Hirsh","year":"1991","journal-title":"N Engl J Med"},{"key":"R8-20250502","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1051\/ject\/201345228","article-title":"Heparin dose and postoperative bleeding in patients undergoing cardiopulmonary bypass.","volume":"45","author":"Rosin","year":"2013","journal-title":"J Extra Corpor Technol"},{"key":"R9-20250502","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/S0022-2143(96)80009-6","article-title":"Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin:platelet factor 4 complexes.","volume":"128","author":"Visentin","year":"1996","journal-title":"J Lab Clin Med"},{"key":"R10-20250502","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1182\/asheducation-2009.1.225","article-title":"Heparin-induced thrombocytopenia: when a low platelet count is a mandate for anticoagulation.","volume":"1","author":"Ortel","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"R11-20250502","doi-asserted-by":"crossref","first-page":"340S","DOI":"10.1378\/chest.08-0677","article-title":"Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).","volume":"133","author":"Warkentin","year":"2008","journal-title":"Chest"},{"key":"R12-20250502","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.athoracsur.2006.09.038","article-title":"Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial.","volume":"83","author":"Koster","year":"2007","journal-title":"Ann Thorac Surg"},{"key":"R13-20250502","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal - full cohort analysis.","volume":"377","author":"Pollack","year":"2017","journal-title":"N Engl J Med"},{"key":"R14-20250502","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/jcph.1300","article-title":"Dabigatran as a treatment option for heparin-induced thrombocytopenia.","volume":"59","author":"Nasiripour","year":"2019","journal-title":"J Clin Pharmacol"},{"key":"R15-20250502","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1160\/TH09-11-0758","article-title":"Dabigatran etexilate\u2013a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.","volume":"103","author":"van Ryn","year":"2010","journal-title":"Thromb Haemost"},{"key":"R16-20250502","doi-asserted-by":"crossref","first-page":"665","DOI":"10.5858\/arpa.2014-0170-OA","article-title":"Use of thromboelastography (TEG) for detection of new oral anticoagulants.","volume":"139","author":"Dias","year":"2015","journal-title":"Arch Pathol Lab Med"},{"key":"R17-20250502","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12959-017-0137-1","article-title":"Perioperative management of patients on direct oral anticoagulants.","volume":"15","author":"Dubois","year":"2017","journal-title":"Thromb J"},{"key":"R18-20250502","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1053\/j.jvca.2008.08.004","article-title":"Cardiopulmonary bypass duration is an independent predictor of morbidity and mortality after cardiac surgery.","volume":"22","author":"Salis","year":"2008","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"R19-20250502","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing.","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc Series B"},{"key":"R20-20250502","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1749-8090-6-44","article-title":"Lepirudin as an alternative to \u201cheparin allergy\u201d during cardiopulmonary bypass.","volume":"6","author":"Parissis","year":"2011","journal-title":"J Cardiothorac Surg"},{"key":"R21-20250502","doi-asserted-by":"crossref","first-page":"106","DOI":"10.4103\/0970-9185.92458","article-title":"Challenges encountered with argatroban anticoagulation during cardiopulmonary bypass.","volume":"28","author":"Agarwal","year":"2012","journal-title":"J Anaesthesiol Clin Pharmacol"},{"key":"R22-20250502","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.jvca.2006.08.011","article-title":"Alternative anticoagulation management strategies for the patient with heparin-induced thrombocytopenia undergoing cardiac surgery.","volume":"21","author":"Murphy","year":"2007","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"R23-20250502","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.athoracsur.2011.01.032","article-title":"Successful use of hirudin during cardiac surgery using minimized extracorporeal circulation in patients with heparin-induced thrombocytopenia.","volume":"92","author":"Haneya","year":"2011","journal-title":"Ann Thorac Surg"},{"key":"R24-20250502","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/0267659118813043","article-title":"A 24-hour perioperative case study on argatroban use for left ventricle assist device insertion during cardiopulmonary bypass and veno-arterial extracorporeal membrane oxygenation.","volume":"34","author":"Fernandes","year":"2019","journal-title":"Perfusion"},{"key":"R25-20250502","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1177\/0310057X0102900613","article-title":"r-hirudin as anticoagulant for cardiopulmonary bypass.","volume":"29","author":"Cameron","year":"2001","journal-title":"Anaesth Intensive Care"},{"key":"R26-20250502","first-page":"115","article-title":"Bivalirudin anticoagulation for cardiopulmonary bypass: an unusual case.","volume":"34","author":"Nikolaidis","year":"2007","journal-title":"Tex Heart Inst J"},{"key":"R27-20250502","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1055\/s-0037-1602664","article-title":"Heparin-induced thrombocytopenia in cardiac surgery patients.","volume":"43","author":"Pishko","year":"2017","journal-title":"Semin Thromb Hemost"},{"key":"R28-20250502","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1051\/ject\/200537296","article-title":"Use of bivalirudin as an anticoagulant during cardiopulmonary bypass.","volume":"37","author":"Veale","year":"2005","journal-title":"J Extra Corpor Technol"},{"key":"R29-20250502","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1051\/ject\/200537319","article-title":"The emergency use of recombinant hirudin in cardiopulmonary bypass. 1999.","volume":"37","author":"Johnston","year":"2005","journal-title":"J Extra Corpor Technol"},{"key":"R30-20250502","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.redar.2012.05.036","article-title":"[Massive haemorrhage after bivalirudin anticoagulation in two heart transplant patients].","volume":"60","author":"Tauron","year":"2013","journal-title":"Rev Esp Anestesiol Reanim"},{"key":"R31-20250502","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jtcvs.2005.09.057","article-title":"A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study.","volume":"131","author":"Dyke","year":"2006","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R32-20250502","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.healun.2006.02.010","article-title":"Argatroban, bivalirudin, and lepirudin do not decrease clot propagation and strength as effectively as heparin-activated antithrombin in vitro.","volume":"25","author":"Nielsen","year":"2006","journal-title":"J Heart Lung Transplant"},{"key":"R33-20250502","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves.","volume":"369","author":"Eikelboom","year":"2013","journal-title":"N Engl J Med"},{"key":"R34-20250502","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/j.thromres.2010.06.011","article-title":"In vitro comparison of dabigatran, unfractionated heparin, and low-molecular-weight heparin in preventing thrombus formation on mechanical heart valves.","volume":"126","author":"Maegdefessel","year":"2010","journal-title":"Thromb Res"},{"key":"R35-20250502","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3109\/08941939.2011.616256","article-title":"Dabigatran versus warfarin after mechanical mitral valve replacement in the swine model.","volume":"25","author":"Schomburg","year":"2012","journal-title":"J Invest Surg"},{"key":"R36-20250502","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1016\/j.jcin.2019.07.059","article-title":"Dabigatran dual therapy versus warfarin triple therapy post-PCI in patients with atrial fibrillation and diabetes.","volume":"12","author":"Maeng","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"key":"R37-20250502","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.bja.2018.04.025","article-title":"Ongoing redistribution of dabigatran necessitates repetitive application of idarucizumab.","volume":"121","author":"Hegemann","year":"2018","journal-title":"Br J Anaesth"},{"key":"R38-20250502","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1213\/ANE.0000000000004419","article-title":"Whole blood point-of-care testing for incomplete reversal with idarucizumab in supratherapeutic dabigatran.","volume":"130","author":"Takeshita","year":"2020","journal-title":"Anesth Analg"}],"container-title":["Anesthesia &amp; Analgesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1213\/ANE.0000000000005089","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:29:02Z","timestamp":1786112942000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1213\/ANE.0000000000005089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,20]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1213\/ane.0000000000005089","relation":{},"ISSN":["0003-2999"],"issn-type":[{"value":"0003-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8,20]]}}}